Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Additional Information (Detail)

v3.23.2
Research and Development Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2021
Sep. 30, 2018
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Research And Development Collaboration Agreements [Line Items]                
Revenue from collaborative arrangement     $ 6,865   $ 4,417 $ 43,494 $ 12,903  
Deferred revenue, current     16,409     16,409   $ 45,573
Deferred revenue, long-term     19     19   5,904
Grants revenue receivable     274     274    
Research and development revenue                
Research And Development Collaboration Agreements [Line Items]                
Revenue from collaborative arrangement     6,627   4,417 40,254 12,903  
Additional Funding Agreement Terms [Member] | Grant                
Research And Development Collaboration Agreements [Line Items]                
Grants revenue receivable     300     300   0
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms [Member] | Bristol Myers Squibb                
Research And Development Collaboration Agreements [Line Items]                
Upfront payment $ 70,000              
Transaction price allocated to performance obligations 70,000              
Deferred revenue, current     16,400     16,400   45,300
Deferred revenue, long-term     0     0   5,900
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms [Member] | Bristol Myers Squibb | Maximum [Member]                
Research And Development Collaboration Agreements [Line Items]                
Milestone payments receivable if option is exercised 874,500              
Additional milestone payments receivable if option is exercised $ 450,000              
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms [Member] | Bristol Myers Squibb | Research and development revenue                
Research And Development Collaboration Agreements [Line Items]                
Revenue from collaborative arrangement     6,600   4,400 40,300 10,300  
Bristol Myers Squibb Collaboration Agreement | License Agreement Terms, Target Completion [Member] | Bristol Myers Squibb | Research and development revenue                
Research And Development Collaboration Agreements [Line Items]                
Revenue from collaborative arrangement       $ 25,800        
Takeda Multi Target Agreement | License Agreement Terms [Member] | Takeda Pharmaceuticals Inc                
Research And Development Collaboration Agreements [Line Items]                
Deferred revenue     0     0   $ 0
Takeda Multi Target Agreement | License Agreement Terms [Member] | Takeda Pharmaceuticals Inc | Research and development revenue                
Research And Development Collaboration Agreements [Line Items]                
Revenue from collaborative arrangement     0   0 0 2,600  
CPRIT Agreement | Cancer Prevention and Research Institute of Texas | Grant                
Research And Development Collaboration Agreements [Line Items]                
Reimbursement amounts submitted in excess of amounts received are recorded as receivables           3,200    
CPRIT Agreement | Additional Funding Agreement Terms [Member] | Cancer Prevention and Research Institute of Texas | Grant                
Research And Development Collaboration Agreements [Line Items]                
Revenue from collaborative arrangement     $ 200     $ 12,600    
Product development grant awarded   $ 15,200            
Reimbursement amounts submitted in excess of amounts received are recorded as receivables         $ 0   $ 0